GH Research PLC (GHRS)

NASDAQ: GHRS · IEX Real-Time Price · USD
11.20
+0.25 (2.28%)
Dec 7, 2022 4:00 PM EST - Market closed
2.28%
Market Cap 569.63M
Revenue (ttm) n/a
Net Income (ttm) -9.96M
Shares Out 52.02M
EPS (ttm) -0.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 46,360
Open 10.65
Previous Close 10.95
Day's Range 10.48 - 11.69
52-Week Range 8.72 - 26.53
Beta n/a
Analysts Buy
Price Target 46.72 (+317.1%)
Earnings Date Dec 5, 2022

About GHRS

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT pro... [Read more]

Industry Biotechnology
IPO Date Jun 25, 2021
Employees 14
Stock Exchange NASDAQ
Ticker Symbol GHRS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for GHRS stock is "Buy." The 12-month stock price forecast is 46.72, which is an increase of 317.14% from the latest price.

Price Target
$46.72
(317.14% upside)
Analyst Consensus: Buy
Stock Forecasts

News

7 Short-Squeeze Stocks for Bold Contrarians to Consider

Throughout much of the new normal, the concept of short-squeeze stocks took off like wildfire. Essentially, this tactic centers on taking a contrarian bet against bearish traders in Wall Street's versio...

2 weeks ago - InvestorPlace

GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates

DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological diso...

3 weeks ago - GlobeNewsWire

New Strong Buy Stocks for October 24th

BXRX, WOLF, GHRS, RKDA and BHR have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2022.

Other symbols: BHRBXRXRKDAWOLF
1 month ago - Zacks Investment Research

Wall Street Analysts See a 262% Upside in GH Research PLC (GHRS): Can the Stock Really Move This High?

The consensus price target hints at a 262% upside potential for GH Research PLC (GHRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings esti...

2 months ago - Zacks Investment Research

7 Psychedelics Stocks to Buy for a Big Drug Boom

Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts and s...

Other symbols: ATAICMPSCYBNENVBMNMD
3 months ago - InvestorPlace

Wall Street Analysts Predict a 206% Upside in GH Research PLC (GHRS): Here's What You Should Know

The mean of analysts' price targets for GH Research PLC (GHRS) points to a 205.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a...

3 months ago - Zacks Investment Research

GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates

DUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological diso...

3 months ago - GlobeNewsWire

GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates

DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disor...

6 months ago - GlobeNewsWire

GH Research Reports Full Year 2021 Financial Results and Provides Business Updates

DUBLIN, Ireland., March 28, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological di...

8 months ago - GlobeNewsWire

Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today

Revive Therapeutics (OTC:RVVTF) shares closed up 14.94% at $0.25 ATAI Life Sciences (NASDAQ:ATAI) shares closed up 3.53% at $5.58

10 months ago - Benzinga

GH Research Announces Positive Trial Results For Treatment-Resistant Depression

Clinical-stage biopharmaceutical company GH Research PLC (NASDAQ: GHRS) announced positive results from recent clinical trials of its leading 5-MeO-DMT formula, a therapy candidate for patients sufferin...

1 year ago - Benzinga

GH Research Posts Data From Treatment-Resistant Depression Trial

GH Research PLC (NASDAQ: GHRS) has reported the outcome of the Phase 2 part of a Phase 1/2 trial of GH001, an inhalable 5-MeO-DMT product candidate for treatment-resistant depression (TRD). The trial me...

1 year ago - Benzinga

GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates

DUBLIN, Ireland, Dec. 06, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological diso...

1 year ago - GlobeNewsWire

GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results

DUBLIN, Ireland, Sept. 23, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological dis...

1 year ago - GlobeNewsWire

7 Companies Go Public Today. What Investors Need to Know.

Acurx Pharmaceuticals, Alpha Teknova, Elevation Oncology, GH Research, Graphite Bio, and MissFresh are listed on the Nasdaq. Mister Car Wash is trading the New York Stock Exchange.

Other symbols: ELEVGRPHMCWTKNOACXPMF
1 year ago - Barrons